This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.
Patients aged 18 years old or more
ECOG 0 to 2
Histologically proven non-small cell lung cancer
Stage III non-metastatic tumor, not allowing for immediate surgery
Positive EGFR mutation
Exercise-induced dyspnea associated with heart failure equal to or greater than stage III of the New York Heart Association (NYHA) classification, (appendix 3)
Coronary syndrome or heart failure in the last three months
Pulmonary function test contraindicating radiotherapy: PFT-FEV1 inferior to 1 L.